Top-Rated StocksTop-RatedNASDAQ:ACLX Arcellx (ACLX) Stock Forecast, Price & News $35.15 -0.73 (-2.03%) (As of 10:14 AM ET) Add Compare Share Share Today's Range$35.15▼$36.0050-Day Range$33.06▼$37.4052-Week Range$16.97▼$48.92Volume18,133 shsAverage Volume494,991 shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$53.42 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcellx MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.9% Upside$53.42 Price TargetShort InterestBearish17.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 3 Articles This WeekInsider TradingSelling Shares$201,390 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.19) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector669th out of 969 stocksBiological Products, Except Diagnostic Industry105th out of 162 stocks 3.5 Analyst's Opinion Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.42, Arcellx has a forecasted upside of 48.9% from its current price of $35.88.Amount of Analyst CoverageArcellx has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.71% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arcellx has recently decreased by 6.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcellx does not currently pay a dividend.Dividend GrowthArcellx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACLX. Previous Next 3.6 News and Social Media Coverage News SentimentArcellx has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arcellx this week, compared to 2 articles on an average week.Search Interest4 people have searched for ACLX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $201,390.00 in company stock.Percentage Held by InsidersOnly 5.86% of the stock of Arcellx is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcellx are expected to grow in the coming year, from ($2.19) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcellx is -9.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcellx is -9.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcellx has a P/B Ratio of 7.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcellx (NASDAQ:ACLX) StockArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.Read More ACLX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACLX Stock News HeadlinesOctober 2, 2023 | americanbankingnews.comArcellx, Inc. (NASDAQ:ACLX) Short Interest Down 6.1% in SeptemberSeptember 19, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Aclaris Therapeutics (ACRS), Incyte (INCY)October 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 6, 2023 | seekingalpha.comArcellx: Clinical Hold Lifted, Charting A Brighter Path Forward (Rating Upgrade)September 4, 2023 | finance.yahoo.comWall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to TradeAugust 20, 2023 | finance.yahoo.comThe Arcellx, Inc. (NASDAQ:ACLX) Analysts Have Been Trimming Their Sales ForecastsAugust 17, 2023 | msn.comBaird Maintains Arcellx (ACLX) Outperform RecommendationAugust 17, 2023 | finance.yahoo.comDoes Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect?October 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 16, 2023 | markets.businessinsider.comArcellx: Partial Clinical Hold Lifted By FDA On IMMagine-1 Phase 2 Trial; Q2 Net Loss NarrowsAugust 15, 2023 | markets.businessinsider.comAnalysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic PotentialAugust 15, 2023 | msn.comNeedham Reiterates Arcellx (ACLX) Buy RecommendationAugust 8, 2023 | benzinga.comArcellx Chief Medical Officer Trades $106K In Company StockJuly 31, 2023 | finance.yahoo.comArcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last yearJuly 25, 2023 | finance.yahoo.comShould You be Bullish on Arcellx (ACLX)?July 6, 2023 | benzinga.comChief Medical Officer of Arcellx Makes $95K SaleJune 21, 2023 | seekingalpha.comArcellx's CAR-T Hold: Turmoil, Triumphs, And Trading TipsJune 20, 2023 | proactiveinvestors.comArcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient deathJune 20, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLXJune 20, 2023 | markets.businessinsider.comAnalyst Ratings for ArcellxJune 20, 2023 | markets.businessinsider.comArcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock FallsJune 20, 2023 | msn.comWhy Arcellx (ACLX) Stock Is NosedivingJune 20, 2023 | finance.yahoo.comArcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's DeathJune 20, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Arcellx Inc (ACLX)June 20, 2023 | nasdaq.comArcellx : FDA Places Clinical Hold On CART-ddBCMA IND For Treatment Of R/R Multiple MyelomaMay 28, 2023 | sg.finance.yahoo.comArcellx, Inc. (ACLX) stock price, news, quote & history – Yahoo FinanceMay 18, 2023 | msn.comThe Latest Analyst Ratings for ArcellxSee More Headlines Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address ACLX Company Calendar Last Earnings8/14/2023Today10/01/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACLX CUSIPN/A CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees98Year FoundedN/APrice Target and Rating Average Stock Price Forecast$53.42 High Stock Price Forecast$104.00 Low Stock Price Forecast$39.00 Forecasted Upside/Downside+48.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,680,000.00 Net MarginsN/A Pretax Margin-568.13% Return on Equity-46.20% Return on Assets-25.29% Debt Debt-to-Equity Ratio0.03 Current Ratio3.57 Quick Ratio3.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.68 per share Price / Book7.67Miscellaneous Outstanding Shares48,360,000Free Float45,525,000Market Cap$1.74 billion OptionableNot Optionable Beta-0.68 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Rami Elghandour (Age 44)Chairman, CEO & Pres Comp: $1.02MMs. Michelle Lim Gilson (Age 30)Chief Financial Officer Comp: $832.8kDr. Christopher R. Heery M.D. (Age 43)Chief Medical Officer Comp: $688.55kMr. Michael Dombeck M.B.A.Chief Operating OfficerMr. Narinderjeet Singh M.S. (Age 51)Chief Technical Officer Mr. David Tice Ph.D. (Age 52)Chief Scientific Officer Ms. Myesha LacyVP of Investor RelationsMs. Maryam Abdul-Kareem J.D.M.S., Gen. CounselMs. Kate AikenChief People OfficerMr. Neeraj P. Teotia (Age 48)Chief Commercial Officer More ExecutivesKey CompetitorsRecursion PharmaceuticalsNASDAQ:RXRXVericelNASDAQ:VCELSpringWorks TherapeuticsNASDAQ:SWTXBeam TherapeuticsNASDAQ:BEAMBioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 16,482 shares on 9/21/2023Ownership: 0.156%Perceptive Advisors LLCBought 174,658 shares on 8/24/2023Ownership: 8.305%Affinity Asset Advisors LLCBought 23,441 shares on 8/21/2023Ownership: 0.468%California State Teachers Retirement SystemBought 61,534 shares on 8/21/2023Ownership: 0.178%Teachers Retirement System of The State of KentuckySold 1,528 shares on 8/21/2023Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions ACLX Stock - Frequently Asked Questions Should I buy or sell Arcellx stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares. View ACLX analyst ratings or view top-rated stocks. What is Arcellx's stock price forecast for 2023? 10 analysts have issued 12 month target prices for Arcellx's stock. Their ACLX share price forecasts range from $39.00 to $104.00. On average, they expect the company's share price to reach $53.42 in the next year. This suggests a possible upside of 48.9% from the stock's current price. View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts. How have ACLX shares performed in 2023? Arcellx's stock was trading at $30.98 at the start of the year. Since then, ACLX shares have increased by 15.8% and is now trading at $35.88. View the best growth stocks for 2023 here. Are investors shorting Arcellx? Arcellx saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 6,200,000 shares, a decrease of 6.1% from the August 31st total of 6,600,000 shares. Based on an average daily volume of 440,500 shares, the short-interest ratio is presently 14.1 days. Approximately 17.7% of the company's shares are sold short. View Arcellx's Short Interest. When is Arcellx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ACLX earnings forecast. How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.18. The business earned $14.30 million during the quarter, compared to the consensus estimate of $82.38 million. What ETFs hold Arcellx's stock? ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED). When did Arcellx IPO? (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share. What is Arcellx's stock symbol? Arcellx trades on the NASDAQ under the ticker symbol "ACLX." How do I buy shares of Arcellx? Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcellx's stock price today? One share of ACLX stock can currently be purchased for approximately $35.88. How much money does Arcellx make? Arcellx (NASDAQ:ACLX) has a market capitalization of $1.74 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis. How can I contact Arcellx? The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com. This page (NASDAQ:ACLX) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.